Drug profile · INN
teprotumumab-trbw
TEPEZZA
teprotumumab-trbw (TEPEZZA) is a insulin-like growth factor i receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — teprotumumab-trbw
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
teprotumumab-trbw (TEPEZZA) is a insulin-like growth factor i receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin-like growth factor I receptor antagonist
Primary target: Insulin-like growth factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is teprotumumab-trbw?
teprotumumab-trbw (TEPEZZA) is a insulin-like growth factor i receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for teprotumumab-trbw?
TEPEZZA is a marketed brand name for teprotumumab-trbw. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of teprotumumab-trbw?
teprotumumab-trbw has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.